Track topics on Twitter Track topics that are important to you
Leading melanoma treatments may have a differentiation problem
Two melanoma treatments are comfortably ahead of the pack in the EU5, earning by far the highest satisfaction scores from medical oncologists. Can either one pull ahead? It won't be easy. According to our survey, doctors recommend these brands for largely the same reasons, and may even see them as interchangeable.
Find out how doctors rated your brand, get insight into why, and learn what you can do to stand out from competitors in FirstView's NPS+ Melanoma 2017 EU5.
Building on the respected net promoter score NPS, the report compares seven major melanoma drugs with easytouse KPIs that highlight ways you can improve brand health. You'll also see how loyal doctors are to your brand, learn which promotional messages resonate best, and find out what doctors think in a unique Brand DNA section.
Insight into 7 Major Melanoma Brands
A Report Based on Expert Knowledge
We surveyed 150 medical oncologists and dermatooncologists from the EU5 countries France, Italy, Germany, Spain, UK, chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.
We conducted the survey between May 3rd and 9th, 2017.
Explore Important Brand Loyalty Issues
NPS+ Melanoma 2017 EU5 explores key issues affecting brand loyalty for drug manufacturers. You'll learn:
What is Net Promoter Score?
NPS is a customer loyalty metric developed by and a registered trademark of Fred Reichheld, Bain Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.
How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:
"How likely are you to recommend this brand to a colleague?"
Responses given on a scale of 0 not at all likely to 10 extremely likelyare used to classify respondents into 3 categories:
How is NPS calculated?
The percentage of detractors the percentage of promoters = NPS.
For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.
NPS can range from 100 everybody is a Detractor to +100 everybody is a Promoter. The higher the score the healthier the brand.
What is FirstView NPS+?
NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty.
Each NPS+ report examines doctors' relationships with the brands used to treat a major disease areameasuring brand loyalty and showing you how it affects your market share. NPS+ also examines brand DNA, revealing in doctors' own words what brands mean to them.
Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Original Article: NPS+ EU5 [Melanoma] [Report Updated: 01062017] Prices from USD $2575NEXT ARTICLE
Melanoma is a highly malignant tumor of melanin-forming cells (melanocytes) There are most commonly found in the skin (resulting from sunlight exposure), but also in the eyes and mucous membranes. Metastasis to other regions of the body is also common....
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...